Skip to main content

Cyclerion Therapeutics Inc (CYCN) Stock

Cyclerion Therapeutics Inc Stock Details, Movements and Public Alerts

Stock Details

Cyclerion Therapeutics Inc (CYCN), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $3.48. Over the past 52 weeks, it has ranged between $1.03 and $8.48. This places the current price at 41.0% of its 52-week high and 238.9% above its 52-week low. Recent trading volume was recorded at 1,057,085. The 14-day Relative Strength Index (RSI) stands at 91.18, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $1.58 by 120.25%. Similarly, it is above its 200-day moving average of $2.07 by 68.12%. The MACD histogram is 0.47, indicating bullish momentum (MACD Line: 0.71, Signal Line: 0.24).

52-Week Range

$8.48 - $1.03

-58.96% from high · +238.85% from low

Avg Daily Volume

13,503,635

20-day average

100-day avg: 3,835,032

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

2.66

EV/EBITDA

0.56

EPS (TTM)

-$1.11

Price to Sales

11.29

Beta

0.95

Less volatile than market

Q:How is CYCN valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is CYCN's risk profile compared to the market?
With a beta of 0.95, Cyclerion Therapeutics Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 2.66 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-170.10%

Operating Margin

-81.80%

EBITDA

$-9,582,000

Return on Equity

-39.30%

Return on Assets

-31.80%

Revenue Growth (YoY)

-43.20%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is CYCN's business model?
Cyclerion Therapeutics Inc achieves a profit margin of -170.10%, meaning it retains $-170.10 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -81.80% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -39.30% and ROA at -31.80%, the company achieves moderate returns on invested capital.
Q:What are CYCN's recent growth trends?
Cyclerion Therapeutics Inc's revenue declined by 43.20% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$23.4M

Revenue (TTM)

$2.07M

Revenue/Share (TTM)

$0.65

Shares Outstanding

3.81M

Book Value/Share

$2.38

Asset Type

Common Stock

Q:What is CYCN's market capitalization and position?
Cyclerion Therapeutics Inc has a market capitalization of $23.4M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 3.81M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does CYCN's price compare to its book value?
Cyclerion Therapeutics Inc's book value per share is $2.38, while the current stock price is $3.48, resulting in a price-to-book (P/B) ratio of 1.46. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$8.00

129.89% upside potential

Analyst Recommendations

No analyst ratings available

Q:How reliable are analyst predictions for CYCN?
0 analysts cover CYCN with 0% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $8.00 implies 129.9% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on CYCN?
Current analyst recommendations:The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Apr 5, 2026, 02:09 AM

Technical Indicators

RSI (14-day)

91.18

Overbought

50-Day Moving Average

$1.58

120.25% above MA-50

200-Day Moving Average

$2.07

68.12% above MA-200

MACD Line

0.71

MACD Signal

0.24

MACD Histogram

0.47

Bullish

Q:What does CYCN's RSI value tell investors?
The RSI (Relative Strength Index) for CYCN is currently 91.18, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret CYCN's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.71 above the signal line at 0.24, with histogram at 0.47. This bullish crossover suggests upward momentum is building. The 50-day MA ($1.58) is below the 200-day MA ($2.07), forming a death cross pattern that often warns of extended weakness. Price is currently above both MAs, confirming strength.

Indicators last updated: Apr 5, 2026, 12:50 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for CYCN and get notified when the price changes.

Stay Ahead of the Market with Cyclerion Therapeutics Inc Alerts

Set up price alerts for Cyclerion Therapeutics Inc and get notified instantly when the price hits your target. Never miss an important price movement again.